Propanc Biopharma Announces Joint Research Partnership with Jaen University, Spain
MELBOURNE, AUSTRALIA -- (Marketwired) -- 07/18/17 -- Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced the establishment of a 4 year joint research partnership with the Jaén University, based in Andalucía, Spain. The primary objective of the partnership is to expand Propanc Biopharma's product pipeline, by discovering new compounds based on the mode of action of naturally derived proenzymes, trypsinogen and chymotrypsinogen, which are the key active ingredients in the Company's lead product, PRP.
The newly established partnership involves the recruitment and co-financing of a doctoral student for a period of up to 4 years, providing 50% of the total cost of the contract, including training of research staff and enrolment in the doctoral program. Dr Macarena Perán Quesada, lecturer at Jaén University, scientific advisor to Propanc Biopharma, will lead the joint research program.
"I am very pleased to announce the execution of the next phase for our POP1 research program, as we look to expand our product pipeline in the future," said James Nathanielsz, Propanc Biopharma's Chief Executive Officer. "Based on years of collaboration and a close, professional relationship with Dr Perán, we have a great deal of confidence in her scientific expertise and understanding of the mechanistic effects of proenzymes as a new therapeutic approach to the treatment and prevention of metastatic cancer. We look forward to the opportunity of identifying and developing new follow on compounds to our lead product, PRP."
In addition to the studentship, preliminary discussions are underway to utilise resources within the one public health network, known as FIBAO, within Granada, Spain, where the aim is to develop shared ideas from the bench to early stage clinical trials. Organizations within FIBAO include Granada University and the University Hospital Complex of Granada, in addition to Jaén University. Professor Juan Marchal and Dr Maria Garcia, both Scientific Advisors to Propanc Biopharma, represent Granada University, and the University Hospital Complex, respectively.
"We have a common vision to develop shared ideas from the bench to early stage human studies within the one public health network, where Propanc Biopharma will assist in driving, leading and ultimately helping to achieve this vision," said Dr Julian Kenyon, Propanc Biopharma's Chief Scientific Officer. "We hope to establish an internationally renowned research and development framework between Propanc Biopharma and leading academic institutions and the University Hospital in Granada, Spain. I am personally very excited to collaborate closely with Propanc Biopharma's scientific advisors to make our vision a reality."
The Company's lead product, PRP, is a solution for once daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen. Currently progressing towards First-In-Human studies, PRP aims to prevent tumor recurrence and metastasis from solid tumors. Eighty percent of all cancers are solid tumors and metastasis is the main cause of patient death from cancer. According to the World Health Organization, 8.2 million people died from cancer in 2012. Consequently, a report by IMS Health states innovative therapies are driving the global oncology market to meet demand, which is expected to reach $150 Billion by 2020. The Company's initial target patient populations are pancreatic, ovarian and colorectal cancers, representing a combined market segment of $14 Billion predicted in 2020, by GBI Research.
To view Propanc Biopharma's "Mechanism of Action" video on anti-cancer product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video
To be added to Propanc Biopharma's email distribution list, please click on the following link: http://ir.propanc.com/email-alerts and submit the online request form.
About Jaén University:
Jaén University is a young and dynamic institution with excellent intellectual capital, demonstrated by its progress in many different fields including Humanities and Education, Experimental Sciences, Health Sciences, Social Sciences, Law, and Engineering, since its creation in 1993. The main objectives of Jaén University is the transfer of knowledge to society in order to have an impact on the economic and social environment, helping, as far as possible, to improve the living conditions of the general population. In this context, The Office of Transfer of Research Results (OTRI) of Jaén University, specializes in channelling the needs of public and private entities towards the university and to promote the transfer of knowledge and technology from the university to the industrial sector. Jaén University has offered 4 PhD studentships this year, to be funded in collaboration with external partners for the training of doctors that will continue their careers in the private sector.
About Propanc Biopharma:
Propanc Biopharma is a clinical stage biopharmaceutical company developing new cancer treatments initially for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds, which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ pancreatic proenzymes, which are inactive precursors of enzymes. In the near term, we intend to target patients with limited remaining therapeutic options for the treatment of solid tumors. In future, we intend to develop our lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, visit: www.propanc.com.
Forward-Looking Statements:
All statements other than statements of historical fact contained herein are "forward-looking statements" for purposes of federal and state securities laws. Forward-looking statements may include the words "may," "will," "estimate," "intend," "continue," "believe," "expect," "plan" or "anticipate" and other similar words. Although we believe that the expectations reflected in our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and to inherent risks and uncertainties including those regarding our earnings, revenues and financial condition, our ability to implement our plans, strategies and objectives for future operations, our ability to execute on proposed new products, services or development thereof, our ability to establish and maintain the proprietary nature of our technology through the patent process, our ability to license from others patents and patent applications, if necessary, to develop certain products, our ability to implement our long range business plan for various applications of our technology, our ability to enter into agreements with any necessary manufacturing, marketing and/or distribution partners for purposes of commercialization, the results of our clinical research and development, competition in the industry in which we operate, overall market conditions, and any statements or assumptions underlying any of the foregoing. Other risks, uncertainties and factors that could cause actual results to differ materially from those projected may be described from time to time in reports we file with the Securities and Exchange Commission, including our reports on Forms 10-K, 10-Q and 8-K. We do not intend, and undertake no obligation, to update any forward-looking statement contained herein, except as required by law.
Investor Contacts:
Consulting for Strategic Growth 1 Ltd
Stan Wunderlich
swunderlich@cfsg1.com
Media Contacts:
Parker Mitchell
parkeramitchell@gmail.com
Source: Propanc Biopharma, Inc.
Released July 18, 2017